Newsletter Signup | Join Community
336
2
Venclexta Imbruvica or Rituxan combination therapy appears more promising than single agent treatment for CLL
The 2nd generation TKI flumatinib appears to control CP-CML better than the historical standard of Gleevec.
ASCO updated reports Calquence has "clinically meaningful" benefit in CLL and may avoid some BTK associated side effects
Imbruvica® Rituxan combination superior to FCR chemotherapy for treatment of newly diagnosed CLL
Beth Israel Deaconess Medical Center doctors vaccine improves outcomes for patients suffering from AML
CLL patients are at increased risk of developing a new cancer including those taking Ibrutinib & BTK Inhibitors
Zydelig® combined with Treanda and Rituxan is and effective treatment of Chronic Lymphocytic Leukemia
considering CAR T for ALL - anyone been through it yet?
looking for others to share their experience with stem cell transplant for leukemia.
